Idefirix (Imlifidase)

What Is Idefirix and What Is It Used For?

Idefirix (imlifidase) is a novel biologic medicine that belongs to the class of immunosuppressive agents. It is specifically designed to address one of the most challenging problems in organ transplantation: the presence of preformed donor-specific antibodies (DSA) that can cause hyperacute or acute antibody-mediated rejection (AMR) of a transplanted kidney. These antibodies, which are a type of immunoglobulin G (IgG), can develop in patients who have been previously exposed to foreign human tissues through prior organ transplants, blood transfusions, or pregnancies.

The active substance, imlifidase, is a cysteine protease enzyme originally derived from the bacterium Streptococcus pyogenes. In its pharmaceutical form, imlifidase is produced using recombinant DNA technology and acts by specifically cleaving all four subclasses of human IgG antibodies. This cleavage breaks IgG molecules into two fragments: F(ab')2 and Fc. By rapidly eliminating circulating IgG, including the harmful donor-specific antibodies, Idefirix creates a temporary therapeutic window during which a kidney transplant can be performed without immediate immunological attack on the donor organ.

Highly sensitized patients represent a significant unmet medical need in transplant medicine. These individuals often accumulate high levels of antibodies against a wide range of human leukocyte antigens (HLA), making it extremely difficult or impossible to find a compatible donor. Many of these patients remain on transplant waiting lists for years or even decades, enduring long-term dialysis with its associated morbidity and reduced quality of life. Idefirix offers these patients a potential path to transplantation by enabling a negative crossmatch conversion, meaning that the test showing incompatibility between patient and donor becomes negative after treatment.

It is important to understand that Idefirix is not a standalone treatment. It is used as part of a comprehensive desensitization protocol that includes standard immunosuppressive therapy after transplantation to prevent the regeneration of antibodies and subsequent rejection episodes. The transplant team will initiate additional immunosuppressive medications following the procedure to maintain long-term graft survival.

What Should You Know Before Receiving Idefirix?

Contraindications

There are specific situations in which Idefirix must not be administered. Your transplant physician will carefully evaluate whether you are a suitable candidate for this treatment. Idefirix is contraindicated in the following circumstances:

• Allergy to imlifidase or any excipient: If you have a known hypersensitivity to imlifidase or any of the other ingredients in the formulation (mannitol, polysorbate 80, trometamol, disodium EDTA dihydrate), you must not receive this medicine.
• Severe active infection: Patients with a severe ongoing infection must not receive Idefirix, as the depletion of IgG antibodies would further compromise the immune system's ability to fight the infection, potentially leading to life-threatening sepsis.
• Thrombotic thrombocytopenic purpura (TTP): This serious blood disorder, in which small blood clots form throughout the body's small blood vessels, is a contraindication for Idefirix treatment due to the risk of worsening the condition.

Warnings and Precautions

Several important warnings and precautions must be considered before and during treatment with Idefirix. These relate primarily to the drug's mechanism of action, which involves the complete depletion of circulating IgG antibodies.

Infusion reactions: Because Idefirix is a protein-based medicine, it can cause allergic reactions in some patients. Prior to the infusion, you will receive premedication (typically corticosteroids and antihistamines) to reduce the risk of an allergic response. If symptoms such as severe rash, difficulty breathing, flushing, or a sensation of warmth develop during the infusion, the infusion rate may be slowed or temporarily stopped. Once symptoms resolve, the infusion can usually be resumed.

Infection risk: IgG antibodies play a critical role in the immune defense against bacterial and viral infections. Since Idefirix eliminates circulating IgG, patients are at significantly increased risk of serious infections in the period following treatment. To mitigate this risk, prophylactic antibiotic therapy is initiated before or at the time of Idefirix administration and continued for an appropriate duration as determined by the transplant team. Patients must be monitored closely for signs of infection, including fever, chills, cough, weakness, or a general feeling of being unwell.

Antibody-mediated rejection (AMR): After the initial depletion of IgG by Idefirix, the body will gradually produce new IgG antibodies. Some of these may be directed against the transplanted kidney (donor-specific antibodies), potentially leading to antibody-mediated rejection. The transplant team will closely monitor for signs of rejection and administer appropriate immunosuppressive therapy to reduce this risk.

Pregnancy and Breastfeeding

Idefirix is not recommended during pregnancy. If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your healthcare provider immediately. The effects of imlifidase on the developing fetus have not been adequately studied, and given that the drug depletes IgG antibodies (which are normally transferred from mother to fetus to provide passive immunity), there is a theoretical risk of harm to the unborn child.

It is not known whether imlifidase passes into breast milk. As a precautionary measure, breastfeeding should be avoided during and for an appropriate period after treatment with Idefirix. Discuss with your healthcare provider the relative benefits and risks of breastfeeding in the context of your treatment.

Children and Adolescents

Idefirix has not been studied in children and adolescents under 18 years of age. The safety and efficacy in this population have not been established, and therefore Idefirix should not be used in patients younger than 18 years.

Important Information About Excipients

This medicine contains less than 1 mmol sodium (23 mg) per dose and is therefore essentially sodium-free. It also contains 0.5 mg polysorbate 80 per mL. Polysorbates can cause allergic reactions in some individuals. Inform your healthcare provider if you have any known allergies to polysorbate-containing products.

How Does Idefirix Interact with Other Drugs?

Drug interactions with Idefirix are primarily driven by its mechanism of action: the rapid cleavage of all IgG molecules. This has significant implications for any therapy that relies on intact IgG antibodies for its efficacy. The transplant team must carefully plan the timing and sequencing of all medications in the peri-transplant period to avoid compromising the effectiveness of co-administered therapies.

It is essential to inform your transplant physician about all medicines you are currently taking, have recently taken, or might take. This includes prescription medicines, over-the-counter medications, and herbal supplements. Your physician will determine whether any dose adjustments or timing modifications are necessary.

Major Interactions

The following IgG-based medications are known to be significantly affected when co-administered with Idefirix. Their efficacy may be substantially reduced or eliminated if given at the same time as Idefirix treatment:

Additional Interactions

The following medications may also be affected by Idefirix co-administration, though their use in the transplant setting may be less common:

What Is the Correct Dosage of Idefirix?

Idefirix is a hospital-only medicine prescribed by physicians experienced in kidney transplantation. The treatment is administered under close medical supervision, and the dose is individually calculated based on the patient's body weight. The medicine is provided as a powder that must be reconstituted and diluted before administration.

Adults

The reconstituted solution is diluted into 50 mL of 0.9% sodium chloride solution and administered through an infusion set with a sterile, non-pyrogenic, low protein-binding in-line filter (0.2 micrometer pore size). At the end of the infusion, the line is flushed with 0.9% sodium chloride solution to ensure the patient receives the full dose.

Prior to administration, premedication is given to reduce the risk of infusion-related reactions. This typically includes corticosteroids and antihistamines. The exact premedication protocol is determined by the transplant center.

Children

Elderly Patients

Reconstitution and Preparation

The preparation of Idefirix for infusion involves a precise process that is performed by trained healthcare professionals in the hospital:

1. Reconstitution: 1.2 mL of sterile water for injections is carefully added to the vial containing the Idefirix powder, directing the water against the glass wall (not directly onto the powder).
2. Dissolution: The vial is gently rotated for at least 30 seconds until the powder is completely dissolved. The vial must not be shaken to avoid foaming.
3. Inspection: The reconstituted solution should be clear to slightly opalescent and colorless to slightly yellow. It must not be used if particles or discoloration are observed.
4. Dilution: The correct volume of reconstituted solution is slowly added to a 50 mL infusion bag containing 0.9% sodium chloride solution. The bag is inverted several times to mix and must be protected from light at all times.

Overdose

Because Idefirix is administered in a controlled hospital setting under direct medical supervision, the risk of overdose is very low. Patients are closely monitored during and after the infusion. Healthcare professionals carefully calculate the dose based on the patient's weight and verify it before administration. If an overdose were to occur, the patient would receive supportive care and be monitored for any adverse effects, particularly an increased risk of infection due to more profound IgG depletion.

What Are the Side Effects of Idefirix?

Like all medicines, Idefirix can cause side effects, although not everyone experiences them. Many side effects are related to the drug's mechanism of action, specifically the depletion of IgG antibodies, which temporarily weakens the immune system. The transplant setting also contributes to the overall risk profile, as patients undergo major surgery and receive multiple immunosuppressive medications simultaneously.

It is crucial to inform your healthcare team immediately if you notice any of the following symptoms, as they may indicate a serious adverse event requiring prompt medical intervention.

Managing Side Effects

Because Idefirix is administered in a hospital setting, the transplant team is prepared to manage side effects promptly. Infusion reactions are typically managed by slowing or temporarily stopping the infusion and administering additional medications such as antihistamines or corticosteroids. Once symptoms resolve, the infusion can usually be resumed at a slower rate.

Infection prevention is a central component of the treatment protocol. Patients receive prophylactic antibiotics starting before or at the time of Idefirix administration. The choice and duration of antibiotic therapy are determined by the transplant center's protocol and may include broad-spectrum antibiotics, antiviral agents, and antifungal medications as appropriate.

Monitoring for transplant rejection involves regular blood tests to assess kidney function, antibody levels, and other relevant markers. If rejection is suspected, a kidney biopsy may be performed to confirm the diagnosis and guide treatment decisions. Rejection episodes are treated with intensified immunosuppressive therapy, which may include pulse corticosteroids, plasmapheresis, or additional biologic agents.

How Should Idefirix Be Stored?

Idefirix is a hospital-use medicine, and its storage is managed by the hospital pharmacy under controlled conditions. Patients do not need to store this medicine at home. However, understanding the storage requirements is important for appreciating the care taken in handling this biological product.

• Unopened vials: Store in a refrigerator at 2–8°C (36–46°F). Do not freeze. Keep in the original carton to protect from light.
• After reconstitution and dilution: Chemical and physical stability has been demonstrated for 24 hours at 2–8°C, including a maximum of 4 hours at 25°C (77°F) within this 24-hour period.
• Shelf life: Use before the expiry date stated on the vial label and carton. The expiry date refers to the last day of the stated month.
• Inspection: Do not use if the reconstituted solution contains particles or is discolored. The solution should be clear to slightly opalescent and colorless to slightly yellow.
• Disposal: Any unused medicine or waste material should be disposed of in accordance with local regulations for biological pharmaceutical waste.

Keep all medicines out of the sight and reach of children, even those stored in hospital settings.

What Does Idefirix Contain?

Active Ingredient

The active substance is imlifidase. Each glass vial contains 11 mg of imlifidase as a white, lyophilized (freeze-dried) powder. After reconstitution with 1.2 mL of sterile water for injections, the resulting solution contains 10 mg/mL of imlifidase, and up to 1.1 mL can be withdrawn from the vial.

Inactive Ingredients (Excipients)

The other ingredients in Idefirix are:

• Mannitol – a sugar alcohol used as a stabilizer and bulking agent in the lyophilized formulation
• Polysorbate 80 – a surfactant that helps maintain protein stability (0.5 mg per mL; may cause allergic reactions in some individuals)
• Trometamol (tromethamine) – a buffer used to maintain the pH of the solution
• Disodium EDTA dihydrate – a chelating agent that helps preserve the formulation
• Hydrochloric acid – used for pH adjustment

Packaging

Idefirix is supplied in glass vials containing the lyophilized powder. Pack sizes are 1 or 2 vials per carton. Not all pack sizes may be marketed in all countries.

Medical Editorial Team

This article was written and medically reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in transplant medicine, nephrology, and clinical pharmacology.